{"name":"Tibotec Pharmaceuticals, Ireland","slug":"tibotec-pharmaceuticals-ireland","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"TMC114","genericName":"TMC114","slug":"tmc114","indication":"Treatment of HIV-1 infection in treatment-experienced adult patients","status":"phase_3"},{"name":"TMC435","genericName":"TMC435","slug":"tmc435","indication":"Treatment of HIV-1 infection","status":"phase_3"},{"name":"Darunavir (DRV)","genericName":"Darunavir (DRV)","slug":"darunavir-drv","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)","status":"phase_3"},{"name":"Ribavirin (R)","genericName":"Ribavirin (R)","slug":"ribavirin-r","indication":"Chronic hepatitis C (in combination with interferon-alpha or direct-acting antivirals)","status":"marketed"},{"name":"TMC-114/RTV","genericName":"TMC-114/RTV","slug":"tmc-114-rtv","indication":"Treatment of HIV-1 infection","status":"phase_3"},{"name":"TMC114/rtv","genericName":"TMC114/rtv","slug":"tmc114-rtv","indication":"Treatment of HIV-1 infection in treatment-experienced adult patients with evidence of viral replication despite receiving an HIV-1 protease inhibitor-based regimen","status":"phase_3"},{"name":"TMC125","genericName":"TMC125","slug":"tmc125","indication":"Treatment of HIV-1 infection","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ovysmen","genericName":"Ovysmen","slug":"ovysmen","indication":"Other","status":"phase_1"},{"name":"TMC278","genericName":"TMC278","slug":"tmc278","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"TMC114","genericName":"TMC114","slug":"tmc114","phase":"phase_3","mechanism":"TMC114 is a protease inhibitor used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection in treatment-experienced adult patients","Treatment of HIV-1 infection in treatment-naive adult patients"],"catalyst":""},{"name":"TMC435","genericName":"TMC435","slug":"tmc435","phase":"phase_3","mechanism":"TMC435 is a protease inhibitor used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"Darunavir (DRV)","genericName":"Darunavir (DRV)","slug":"darunavir-drv","phase":"phase_3","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"Ovysmen","genericName":"Ovysmen","slug":"ovysmen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ribavirin (R)","genericName":"Ribavirin (R)","slug":"ribavirin-r","phase":"marketed","mechanism":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","indications":["Chronic hepatitis C (in combination with interferon-alpha or direct-acting antivirals)","Severe respiratory syncytial virus (RSV) infection","Lassa fever","Hantavirus pulmonary syndrome"],"catalyst":""},{"name":"TMC-114/RTV","genericName":"TMC-114/RTV","slug":"tmc-114-rtv","phase":"phase_3","mechanism":"TMC-114/RTV is a protease inhibitor used in the treatment of HIV-1 infection.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"TMC114/rtv","genericName":"TMC114/rtv","slug":"tmc114-rtv","phase":"phase_3","mechanism":"TMC114/rtv is a protease inhibitor used to treat HIV infection.","indications":["Treatment of HIV-1 infection in treatment-experienced adult patients with evidence of viral replication despite receiving an HIV-1 protease inhibitor-based regimen"],"catalyst":""},{"name":"TMC125","genericName":"TMC125","slug":"tmc125","phase":"phase_3","mechanism":"TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"TMC278","genericName":"TMC278","slug":"tmc278","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQRERCY0JhMnduSDl4OHM4SDhZSzRlWTVycWtMVklHeGhsbWlUQzR2OWx4cmVMYU5ETEd2V1UzZW1ROXg0OGNvdkl0SzE1UWxxd1BvUjVnTl8tMndsQjdDQ0J4SmIyMm9SYXFaTDFlZV91bHpDRU9YNEtQWkh4dGExdlBDUUJDaUQ1QnZKTWJieHlOcGVOTzJyWXA0QlQxeUg5STlrUWNmQQ?oc=5","date":"2013-09-02","type":"trial","source":"Clinical Trials Arena","summary":"Edurant (rilpivirine) for the Treatment of HIV-1 Infection - Clinical Trials Arena","headline":"Edurant (rilpivirine) for the Treatment of HIV-1 Infection","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":6,"phase_1":1,"marketed":2},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}